Amylin sues over Lilly's each-way diabetes bet on exenatide and BI's linagliptin
This article was originally published in Scrip
Executive Summary
Amylin Pharmaceuticals is suing its partner Lilly, claiming that Lilly through its diabetes venture with Boehringer Ingelheim is engaging in anticompetitive activity and breaching its strategic alliance agreements to maximise commercialisation of Byetta (exenatide) and a longer-acting version (Bydureon), currently undergoing FDA review. In particular, Amylin claims Lilly will use the same sales force to sell exenatide as it will for Boehringer's Tradjenta (linagliptin).